Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

174
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
174
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

219
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
219
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

369
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
369
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

205
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
205
Angina IV: Management01:26

Angina IV: Management

236
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
236
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

265
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
265

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

P2Y12 inhibitor monotherapy after abbreviated dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis.

European heart journal·2026
Same author

Should clopidogrel replace aspirin for long-term therapy after percutaneous coronary intervention?

Journal of cardiovascular medicine (Hagerstown, Md.)·2026
Same author

Safety and Efficacy of Colchicine across the Spectrum of Coronary Artery Disease: A Systematic Review and Meta-Analysis of 20 Randomized Trials.

Clinical pharmacology and therapeutics·2026
Same author

Dual antiplatelet therapy escalation and de-escalation.

European heart journal. Acute cardiovascular care·2026
Same author

Long-term outcomes of percutaneous coronary intervention for recurrent events in patients undergoing target-vessel vs. nontarget-vessel revascularization.

Journal of cardiovascular medicine (Hagerstown, Md.)·2025
Same author

Anti-inflammatory strategies for patients with atherosclerotic coronary disease.

Expert review of cardiovascular therapy·2025

Related Experiment Video

Updated: Jan 15, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.6K

Targeting Inflammation After Acute Myocardial Infarction.

Antonino Imbesi1, Antonio Greco1, Marco Spagnolo1

  • 1Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico-San Marco," University of Catania, Catania, Italy.

Journal of the American College of Cardiology
|October 8, 2025
PubMed
Summary
This summary is machine-generated.

Inflammation after acute myocardial infarction (AMI) predicts recurrent cardiovascular events. This review explores anti-inflammatory therapies for secondary prevention, highlighting knowledge gaps and evolving evidence.

Keywords:
anti-inflammatory drugsinflammationmyocardial repairresidual cardiovascular risktargeted therapy

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

5.0K

Related Experiment Videos

Last Updated: Jan 15, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.6K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

5.0K

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Pharmacology

Background:

  • Adverse cardiovascular events persist after acute myocardial infarction (AMI) despite secondary prevention advances.
  • Acute and persistent inflammation post-AMI is a significant predictor of recurrent events and mortality, surpassing low-density lipoprotein cholesterol.
  • Dysregulation of the inflammatory response following AMI can lead to chronic low-grade inflammation and poorer clinical outcomes.

Purpose of the Study:

  • To provide an updated overview of inflammatory mechanisms after AMI.
  • To critically appraise the clinical evidence for anti-inflammatory therapies in secondary cardiovascular prevention.
  • To identify knowledge gaps concerning anti-inflammatory drug class effects, patient selection, and optimal timing.

Main Methods:

  • Literature review of inflammatory mechanisms post-AMI.
  • Critical appraisal of clinical trial data on anti-inflammatory agents.
  • Synthesis of current evidence on anti-inflammatory strategies for secondary cardiovascular prevention.

Main Results:

  • Inflammation plays a crucial role in residual cardiovascular risk after AMI.
  • Several anti-inflammatory drugs are under investigation, but results on efficacy and safety are conflicting.
  • Key knowledge gaps exist regarding optimal use of these therapies.

Conclusions:

  • Modulating inflammation is a promising strategy for secondary prevention after AMI.
  • Further research is needed to address uncertainties in drug choice, patient selection, and timing.
  • Understanding inflammatory pathways is critical for developing effective anti-inflammatory treatments.